Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated

Standard of Care Treatment for GD1

At a Glance

The main treatments for Gaucher disease type 1 (GD1) are Enzyme Replacement Therapy (ERT) delivered via IV infusion, and Substrate Reduction Therapy (SRT) taken as a daily pill. ERT replaces the missing enzyme, while SRT slows down the body's production of fatty waste.

While Gaucher disease type 1 (GD1) is a lifelong condition, modern therapies are designed to either replace the missing enzyme or reduce the amount of waste your body produces [1][2]. Your medical team will work with you to choose between two main categories of treatment [3][4].

Enzyme Replacement Therapy (ERT)

ERT is considered the gold standard and is typically the first-line treatment for both adults and children with GD1 [5][2].

  • How it Works: ERT provides a functional version of the missing glucocerebrosidase enzyme. It is delivered directly into your bloodstream [1][6].
  • Administration: It is given as an intravenous (IV) infusion, usually once every two weeks [7][4]. If stable, many patients can transition to home infusions [4].
  • Available Medications: Imiglucerase, Velaglucerase alfa, and Taliglucerase alfa [8][9][10].

Substrate Reduction Therapy (SRT)

SRT takes a different approach by slowing down the production of the fatty waste (the “substrate”) so that your body’s limited amount of enzyme can keep up [1][11].

  • How it Works: It blocks the first step in the creation of glucosylceramide [1].
  • Administration: This is an oral medication (a pill) taken once or twice daily [7][12].
  • Available Medications: Eliglustat (first-line for specific genetic profiles) and Miglustat (second-line maintenance) [13][14].
  • Pregnancy Safety Warning: Oral SRTs (eliglustat and miglustat) are not recommended during pregnancy or while breastfeeding. Women who are pregnant or planning to conceive typically must use ERT, which is widely used and considered safe during pregnancy.

Is Oral Therapy Right for You?

Choosing an oral medication like eliglustat requires careful screening:

  • Metabolizer Status: Your doctor must perform a CYP2D6 genotyping test to determine how quickly your liver breaks down the drug [13][12].
  • Cardiac Screening: An ECG (electrocardiogram) is often required before starting eliglustat, as it can affect heart rhythms depending on your metabolizer status [13][15].
  • Drug Interactions: Many common medications can interfere with eliglustat [13][16].

What to Expect When Treatment Starts

Treatment works progressively. While every patient is different, you can generally expect:

  • First few months: Energy levels often improve as anemia resolves.
  • 6 to 12 months: Platelet counts usually stabilize, and you should notice a reduction in bruising and bleeding. Your spleen and liver will begin to shrink noticeably.
  • 1 to 2 years: Spleen and liver size will approach normal. Bone pain may decrease, but structural bone changes (like bone density) take the longest to heal and require years of therapy to maximize improvement.

Navigating Treatment Access and Costs

Rare disease therapies are notoriously expensive. However, you do not have to navigate this alone:

  • Specialty Pharmacies: These medications are coordinated through specialized pharmacies that have dedicated teams to help with insurance approvals.
  • Patient Assistance Programs: The pharmaceutical companies that manufacture these drugs offer robust assistance programs that can help cover co-pays or provide free medication if you are uninsured.
  • Financial Navigators: Ask your clinic to connect you with a financial counselor or case manager to help navigate your benefits.

Common questions in this guide

Should I choose IV infusions (ERT) or oral medication (SRT) for GD1?
Your medical team will help you decide based on your lifestyle, genetic profile, and family planning goals. ERT is the gold standard delivered via biweekly IV infusions, while SRT is a daily pill that requires specific genetic and cardiac screening.
Why do I need a genetic test before starting oral SRT?
Your doctor must perform a CYP2D6 genotyping test to see how quickly your liver processes the oral medication eliglustat. This ensures the drug is safe and effective for your specific metabolism.
Are GD1 treatments safe during pregnancy?
Enzyme Replacement Therapy (ERT) is widely used and considered safe during pregnancy. However, oral Substrate Reduction Therapies (SRT) are not recommended for those pregnant or breastfeeding, so patients usually must transition to ERT if planning to conceive.
How long does it take for GD1 treatment to work?
Energy levels and anemia usually improve within the first few months of treatment. Your spleen and liver typically begin to shrink noticeably between 6 and 12 months, while structural bone improvements may take several years of continuous therapy.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my symptoms and lifestyle, am I a better candidate for IV infusions (ERT) or oral medication (SRT)?
  2. 2.What is my CYP2D6 metabolizer status, and do I need an ECG before considering eliglustat?
  3. 3.If I become pregnant or plan to conceive, how will we manage the transition between medications?
  4. 4.Can your office connect me with a financial navigator or patient assistance program to help cover the cost of these therapies?
  5. 5.When can I realistically expect my energy levels to improve and my spleen to shrink?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Hematological manifestations and complications of Gaucher disease.

    Linari S, Castaman G

    Expert review of hematology 2016; (9(1)):51-8 doi:10.1586/17474086.2016.1112732.

    PMID: 26565753
  2. 2

    An Overview of Gaucher Disease.

    Méndez-Cobián DA, Guzmán-Silahua S, García-Hernández D, et al.

    Diagnostics (Basel, Switzerland) 2024; (14(24)) doi:10.3390/diagnostics14242840.

    PMID: 39767201
  3. 3

    Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease.

    Biegstraaten M, Cox TM, Belmatoug N, et al.

    Blood cells, molecules & diseases 2018; (68()):203-208 doi:10.1016/j.bcmd.2016.10.008.

    PMID: 28274788
  4. 4

    Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher disease.

    Kleytman N, Ruan J, Ruan A, et al.

    Molecular genetics and metabolism reports 2021; (29()):100798 doi:10.1016/j.ymgmr.2021.100798.

    PMID: 34485083
  5. 5

    Enzyme Replacement or Substrate Reduction? A Review of Gaucher Disease Treatment Options.

    Van Rossum A, Holsopple M

    Hospital pharmacy 2016; (51(7)):553-63 doi:10.1310/hpj5107-553.

    PMID: 27559188
  6. 6

    Pompe disease: Unmet needs and emerging therapies.

    George KA, Anding AL, van der Flier A, et al.

    Molecular genetics and metabolism 2024; (143(3)):108590 doi:10.1016/j.ymgme.2024.108590.

    PMID: 39418752
  7. 7

    Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe.

    Belmatoug N, Di Rocco M, Fraga C, et al.

    European journal of internal medicine 2017; (37()):25-32 doi:10.1016/j.ejim.2016.07.011.

    PMID: 27522145
  8. 8

    Treatment-naïve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4years in phase 3 trials.

    Zimran A, Elstein D, Gonzalez DE, et al.

    Blood cells, molecules & diseases 2018; (68()):153-159 doi:10.1016/j.bcmd.2016.10.007.

    PMID: 27839979
  9. 9

    Long-Term Outcomes of Disease Modifying Therapies in Gaucher Disease.

    Manisha R, Phadke SR

    Indian journal of pediatrics 2025; (92(6)):585-591 doi:10.1007/s12098-023-04986-y.

    PMID: 38315376
  10. 10

    Ten-Year Follow-Up of Taliglucerase Alfa in Type 1 Gaucher Disease: Real-World Evidence from Albania.

    Cullufi P, Velmishi V, Troja E, et al.

    Journal of clinical medicine 2025; (14(19)) doi:10.3390/jcm14197015.

    PMID: 41096096
  11. 11

    A Quantitative Systems Pharmacology Model of Gaucher Disease Type 1 Provides Mechanistic Insight Into the Response to Substrate Reduction Therapy With Eliglustat.

    Abrams R, Kaddi CD, Tao M, et al.

    CPT: pharmacometrics & systems pharmacology 2020; (9(7)):374-383 doi:10.1002/psp4.12506.

    PMID: 32558397
  12. 12

    Effects of paroxetine, ketoconazole, and rifampin on the metabolism of eliglustat, an oral substrate reduction therapy for Gaucher disease type 1.

    Vu L, Cox GF, Ibrahim J, et al.

    Molecular genetics and metabolism reports 2020; (22()):100552 doi:10.1016/j.ymgmr.2019.100552.

    PMID: 31993325
  13. 13

    How a concentration-effect analysis of data from the eliglustat thorough electrocardiographic study was used to support dosing recommendations.

    Ruskin JN, Ortemann-Renon C, Msihid J, et al.

    Molecular genetics and metabolism 2020; (131(1-2)):211-218 doi:10.1016/j.ymgme.2020.09.003.

    PMID: 33012655
  14. 14

    Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series.

    Serratrice C, Swiader L, Serratrice J

    Journal of medical case reports 2015; (9()):146 doi:10.1186/s13256-015-0617-5.

    PMID: 26100396
  15. 15

    Suicidal attempt with eliglustat overdose.

    Nadler J, Hermanns-Clausen M, Dilger K

    JIMD reports 2023; (64(1)):23-26 doi:10.1002/jmd2.12341.

    PMID: 36636596
  16. 16

    Drug-Drug Interactions Of Amiodarone And Quinidine On The Pharmacokinetics Of Eliglustat In Rats.

    Wang Q, Wang H, Zhong Y, Zhang Q

    Drug design, development and therapy 2019; (13()):4207-4213 doi:10.2147/DDDT.S226948.

    PMID: 31849452

This page provides educational information about standard treatments for Gaucher disease type 1. Always consult your healthcare provider to determine the safest and most effective therapy for your specific needs.

Get notified when new evidence is published on Gaucher disease type 1.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.